{
  "study_id": "NCT05351541",
  "agent": "framework",
  "run": 1,
  "p_primary_hypothesis_supported": 0.82,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": 3, "high": 18, "metric": "Mean change in BPI interference, 0-70 scale, baseline to 1 month (positive = reduction)"},
  "moderator_prediction": "Modafinil (alone or placebo add-on) arms respond more; zolpidem arms respond less. Zolpidem sedates and dulls attention and post-session consolidation, cutting the impact term of the session, while modafinil keeps attention high during the window.",
  "claim_ids_used": ["PM-0401", "PM-0369", "PM-1286", "PM-0092", "PM-0485", "PM-0126", "PM-0109", "PM-0132", "PM-0946", "PM-0146", "PM-0990"],
  "rationale": "Every participant gets psilocybin, preparation and integration in a clinical setting, which the framework reads as a chemical bypass relaxing high-level priors plus therapist authority: two doors at once. Pain interference is a render-layer, self-rated outcome that belief reaches most easily, and 1 month is early enough that a single high-impact session still dominates before fade by starvation. The within-subject pre-post design, with no untreated control and no blinding of the psilocybin itself, adds expectation and regression to the mean. With N of about 30, a moderate drop of about 8-12 points should reach significance. Risks: small sample, variable 1-30 mg dosing, and zolpidem arms blunting the experience."
}